Europe’s Pharmaceutical Industry: Key Insights and Trends

The European pharmaceutical preparations industry is one of the most strategically important sectors in Europe, combining strong revenue generation with high levels of innovation and employment. As a key pillar of healthcare systems, it supports economic growth while ensuring access to essential medicines.

European companies classified under SIC code 2834 operate in the manufacture of finished pharmaceutical products for human and veterinary use. This industry is particularly interesting due to its resilience, strategic importance, and long-term growth potential, while also facing competitive pressure from the U.S. and Asia. As a result, pharmaceutical preparations remain a key sector for economic analysis, investment assessment, and EU industrial policy.

Browse through 80M+ businesses registered in Europe and filter out the ones you need using name, address, identification number, contact details, industry, SIC Code, sales, or number of employees with HitHorizons Screener and HitHorizons API.

Analyzing revenue dynamics, employment distribution, and geographic concentration provides valuable insight into the industry structure, competitiveness, and future trajectory of the European pharmaceutical preparations market.

Revenue Trend

The revenue data for the European pharmaceutical preparations industry shows overall stability followed by renewed growth over the 2022–2024 period. In 2022, total industry revenue amounted to approximately €670.1 billion, followed by a slight decline in 2023 to €669.0 billion, indicating a period of market stabilization after earlier growth.

In 2024, revenue increased significantly to around €710.3 billion, representing approximately 6% growth and marking a strong rebound and clear upward trend. This increase reflects renewed demand, price adjustments, and the continued expansion of high-value pharmaceutical products.

Overall, the data suggests that while the industry experienced a temporary slowdown, its long-term trajectory remains positive, supported by resilient demand for medicines, demographic trends, and ongoing innovation.

Revenue within the industry is also highly concentrated among leading companies. The top 50 companies generated approximately €467.8 billion, accounting for 66% of total industry sales, while the top 15 companies alone contributed around €347.7 billion, representing 49% of total revenue. This concentration highlights the dominant role of large multinational pharmaceutical companies in driving overall industry performance.

Distribution of Companies

The data shows the geographical distribution of companies operating in the European pharmaceutical preparations industry (SIC 2834) in 2024, highlighting a high concentration of firms in a limited number of countries.

Germany hosts the largest number of companies, with 2,367 firms, representing 24% of all companies in the industry. This reflects Germany’s strong pharmaceutical manufacturing base, large domestic market, and well-established industrial infrastructure. The Russian Federation follows with 1,297 companies (13%), indicating a sizable domestic-oriented pharmaceutical sector.

The United Kingdom accounts for 852 companies (9%), while Switzerland, despite its smaller population, hosts 592 companies (6%), underlining its importance as a hub for high-value pharmaceutical activities. Italy and Spain each represent around 5% of total companies, followed closely by Poland, highlighting the growing role of Central and Southern Europe in pharmaceutical manufacturing.

Countries such as France, the Netherlands, Ireland, Greece, Belgium, Denmark, and Sweden each contribute smaller individual shares, typically between 2% and 4%, reflecting more specialized or concentrated industry structures. The “Others” category accounts for 13%, showing that a broad range of smaller European markets collectively plays a meaningful role.

Revenue Concentration by Country

Revenue within the industry is highly concentrated, based on total European pharmaceutical preparations revenue of approximately €710.3 billion. The United Kingdom, with around €140.1 billion (20%), and Germany, generating approximately €136.3 billion (19%), are the dominant markets, together accounting for nearly 40% of total European industry revenue. Ireland follows as the third-largest contributor, with €90.2 billion (13%), reflecting its strong role as a manufacturing and export hub for multinational pharmaceutical companies.

A second tier of countries — France (€58.8 billion, 8%), Denmark (€53.1 billion, 7%), and the Netherlands (€49.9 billion, 7%) — makes a substantial contribution, highlighting the importance of Western and Northern Europe as key pharmaceutical production centers. Belgium and Italy each generate approximately €38.9 billion (5%) and €38.9 billion (5%) respectively, while Sweden (€24.8 billion, 3%), Spain (€17.7 billion, 2%), and the Russian Federation (€11.3 billion, 2%) represent smaller individual shares.

The “Others” category accounts for €50.3 billion (7%), indicating that although numerous smaller European markets participate in the industry, overall revenue is largely driven by a limited number of key countries. This distribution reflects differences in manufacturing scale, concentration of multinational pharmaceutical companies, export orientation, and national regulatory environments across Europe.

Overall, the distribution indicates that while revenue is concentrated in a few major pharmaceutical hubs, the number of companies is more geographically dispersed, suggesting differences in company size, specialization, and market focus across Europe.

Employees Concentration by Country

Employment in the European pharmaceutical preparations industry totals approximately 1,218,365 employees, with the workforce highly concentrated in a limited number of countries, reflecting the geographic distribution of manufacturing, R&D, and corporate headquarters. Germany is the largest employer, with around 308,500 employees, accounting for 25% of total industry employment in Europe, highlighting its role as a major production and innovation hub.

The United Kingdom follows with approximately 261,700 employees (21%), supported by a strong presence of multinational pharmaceutical companies and advanced research infrastructure. Together, Germany and the UK employ nearly half of the total European workforce in this sector.

Other significant contributors include the Russian Federation (8%), Ireland (5%), and Switzerland (5%), reflecting a mix of large domestic markets and export-oriented manufacturing centers. Countries such as Italy, Denmark, Spain, and France each account for around 4–5% of total employment, indicating a broadly distributed but still concentrated labor base.

Overall, the employment structure demonstrates that while pharmaceutical activities are present across Europe, core employment is concentrated in established pharmaceutical hubs, underlining their strategic importance to the industry.

Leading Companies

The European pharmaceutical preparations industry is strongly shaped by a small number of large multinational leaders whose performance reflects broader industry trends such as innovation intensity, portfolio focus, and operational restructuring. AstraZeneca PLC, Novo Nordisk A/S, and GSK PLC illustrate different strategic paths within the sector.

AstraZeneca PLC

AstraZeneca reported strong revenue growth, increasing from €38.8 billion in 2023 to €45.8 billion in 2024, accompanied by an expansion of its workforce from 89,900 to 94,300 employees. This growth was primarily driven by strong demand for innovative medicines, particularly in oncology, cardiovascular, renal, and metabolic therapies. Continued investment in R&D, clinical development, and global manufacturing capacity required additional skilled employees, supporting both revenue expansion and workforce growth. AstraZeneca’s performance reflects an innovation-led growth strategy, where pipeline strength and global market penetration translate into higher sales and headcount.

Novo Nordisk A/S

Novo Nordisk experienced one of the most pronounced expansions among leading European pharmaceutical companies. Revenue rose sharply from €31.1 billion in 2023 to €38.9 billion in 2024, while employee numbers increased significantly from 64,319 to 77,349. This growth was largely driven by exceptionally strong global demand for diabetes and obesity treatments, particularly blockbuster GLP-1 therapies such as Ozempic, positioning Novo Nordisk as a leader in a rapidly expanding therapeutic segment. To support increased production volumes, supply chain expansion, and ongoing R&D, the company substantially scaled its workforce. The data highlights Novo Nordisk’s role as a high-growth specialist, where revenue acceleration directly translates into employment growth.

GSK PLC

GSK showed a more moderate revenue increase, from €35.2 billion in 2023 to €36.4 billion in 2024, while reducing its workforce from 70,212 to 68,629 employees. This divergence reflects GSK’s focus on portfolio optimization and operational efficiency following prior restructuring initiatives. The company has concentrated investment on core areas such as vaccines and specialty medicines while streamlining non-core operations. As a result, revenue growth was achieved without workforce expansion, indicating a shift toward cost control, productivity improvements, and selective investment rather than broad-based scaling.

Browse through all companies registered in Europe and filter them by name, address, identification number, contact details, industry, SIC Code, sales, or even the number of employees with HitHorizons Screener and HitHorizons API.

Together, these companies demonstrate how different strategic models coexist within the European pharmaceutical preparations industry. High-growth, innovation-driven firms tend to combine revenue expansion with workforce growth, while more mature players increasingly pursue efficiency-driven growth, maintaining or increasing revenue with a leaner organizational structure. This dynamic underlines the industry’s dual nature: both a rapidly innovating sector and a highly disciplined, cost-conscious manufacturing environment.